Iwasaki Eisuke, Fukuhara Seiichiro, Horibe Masayasu, Kawasaki Shintaro, Seino Takashi, Takimoto Yoichi, Tamagawa Hiroki, Machida Yujiro, Kayashima Atsuto, Noda Marin, Hayashi Hideyuki, Kanai Takanori
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Diagnostics (Basel). 2021 Mar 8;11(3):469. doi: 10.3390/diagnostics11030469.
Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment.
胰腺癌是最致命的实体恶性肿瘤，且胰腺癌患者数量正在增加。全身化疗对此类患者往往无效，因此迫切需要个性化医疗。与其他类型的癌症不同，胰腺癌的个性化治疗仍在研发中。因此，胰腺癌对抗癌药物不太敏感，且常常对常规治疗具有耐药性。所以，胰腺癌个性化医疗取得进展很有必要。本综述探讨了胰腺癌个性化医疗的进展，包括内镜超声（EUS）引导下采样的应用。EUS引导下采样广泛用于诊断胰腺肿瘤，并有望应用于采样组织。此外，使用EUS引导下采样的临床研究也有所增加。基于使用患者来源类器官的高通量药物敏感性测试的基因组检测和药理特征的精准医学相结合，有望彻底改变胰腺癌的治疗方式。
